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Cancer cells often lose expression of the p53 protein or express mutant forms of 
p53. Some of these mutant p53 proteins, called gain-of-function mutant p53, have 
gained oncogenic functions. Previously, our group observed mutant p53 R273H 
interacts with replicating DNA and upregulates the chromatin localization of several 
DNA replication factors including PCNA, MCM2-7, and PARP1 (termed the mtp53-
PARP-MCM axis).  In this thesis, we explore the contribution of mutant p53 and PARP1 
in castration-resistant prostate cancer (mutant p53 P223L and V274F) and triple-
negative breast cancer (mutant p53 R273H). In the castration-resistant prostate cancer 
cell line DU145, we examine two mutant p53 proteins, P223L and V274F, for 
participation in the mtp53-PARP-MCM axis. We observed that these mutations were not 
drivers of sensitivity to DNA damage and PARP inhibition.  
In the triple-negative breast cancer cell line MDA-MB-468, we examined the role 
of the R273H C-terminal basic domain, in the mtp53-PARP-MCM axis. We 
hypothesized that the C-terminal domain in mutant p53 R273H facilitates chromatin 
recruitment of PARP1. This work compared CRISPR-Cas9-edited MDA-MB-468 cells 
with truncations in the C-terminal domain (R273H∆381-388), the C-terminal and 
oligomerization domain (R273H∆347-393) and a frameshift resulting in very low mutant 
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p53 expression (R273Hfs387). Mutant p53 R273H C-terminal domain truncations 
decreased proliferation rate, as well as chromatin-, PAR-, and PARP1-binding. 
Interestingly, the cells expressing R273H∆347-393 had the lowest proliferation rate, 
least chromatin interaction with PARP1 and PAR, had no delay in cell cycle 
progression, and exhibited the fastest DNA replication speed. As such, increased DNA 
replication fork speeds have been reported to occur when PARP1 is inhibited, indicating 
that loss of R273H amino acids 347-393 may result in decreased PARP1 function and a 
decrease in cancer cell survival. The mutant p53 R273H C-terminal domain participates 
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1.1 Wild-type p53 
1.1.1 Discovery and origins of p53 as a tumor suppressor 
The tumor suppressor protein p53 has been one of the most closely studied 
human proteins in human history since its first description in 19791. Initially found bound 
to SV-40 large T-antigen, p53 was thought to be an oncogene capable of transforming 
cells1. Several years later, researchers uncovered alterations in the TP53 gene leading 
to a loss of protein expression in transformed HL-60 leukemia cells, leading to the first 
sign of p53 as a tumor suppressor2. Another significant step forward for the 
classification of p53 as a tumor suppressor occurred when it was observed that 
colorectal cancers, and later many other types of cancers, consistently contain deleted 
or rearranged sequences in chromosome 17, where the TP53 gene is encoded, further 
cementing p53 as a classical tumor suppressor3-6. Follow-ups to these observations led 
to the validation of p53 as a bona fide tumor suppressor when it was seen in colorectal 
cancer that p53 experienced a loss of heterozygosity along with a mutant allele, 
indicating that no wild-type p53 expression was found in examined tumors7. This 
revelation indicated that p53 follows Alfred Knudson’s two-hit hypothesis of tumor 
suppressors where both alleles of a tumor suppressor must be inactivated to impart a 
phenotype8. Many years later, an astonishing amount of information is known about p53 
and even more astonishing is that there are many more mysteries to uncover. 
1.1.2 Structure and Domains of p53 
 The p53 protein is comprised of two N-terminal transactivation domains (amino 
acid residues 1-73), a proline-rich region (residues 63-97), a central DNA-binding 
domain (residues 94-312), an oligomerization domain (residues 324-355), and a C-
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terminal basic domain (residues 364-393) (Fig.1.1). The transactivation domains of p53 
often work in tandem to facilitate recruitment of RNA pol II onto target gene promoters. 
The proline rich region contributes to functional transcriptional activation. The p53 
oligomerization domain contains a β-strand, a tight turn at glycine 334, followed by an α-
helix. Interactions between β-strands allow for dimer formation, and interactions 
between dimeric α-helices form the functional tetramer, leading to the description of the 
p53 tetramer as a symmetrical dimer of dimers with the oligomerization domain being 
critical for forming this quaternary structure9. The core binding domain is responsible for 
recognition of p53 response elements at proximal and distal enhancers of p53 target 
genes. There is an additional non-specific DNA binding domain within p53 called the C-
Figure 1.1 Functional domains of p53 and common mutation sites 
The p53 protein is shown with characterized functional domains, as well as the most 
frequently mutated amino acid residues in the DNA binding domain. Also shown are the 
basic amino acids within the C-terminal basic domain, where electrostatic interactions 
between lysine and DNA mediate p53 binding to DNA independent of sequence. 
Abbreviations: NTD – N-terminal Transactivation Domains, PR - Proline-rich Region, 
OD - Oligomerization Domain, CTD - C-terminal Basic Domain; Adapted from Laptenko, 
2016 and Joerger, 2010. 
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terminal basic domain (CTD) which binds DNA independent of sequence10,11. This 
binding occurs through electrostatic interactions between six lysine residues (residues 
370, 372, 373, 381, 382, and 386), and the DNA phosphate backbone12. The CTD has 
been shown to be responsible for one-dimensional linear diffusion along DNA as part of 
a mechanism to find p53 response elements and is critical to p53 stability and functional 
regulation13-15. 
1.1.3 The p53 Consensus Sequence 
As a transcription factor, p53 must find and bind to its consensus sequence 
element, found in several locations across the genome, to activate transcription by 
recruitment of RNA pol II16,17. The consensus sequence for p53 has a large degree of 
flexibility with regards to the specific nucleotide sequence, but the half-site follows the 
palindromic order of RRRCWWGYYY (where R is a purine- ie either A/G, and W is 
either A/T, and Y is pyrimidine- ie either C/T), followed by a spacer of between 0-18 
nucleotides, and a second half-site18,19. The orientation of half-sites in relation to one 
another can be varied, observed as head-to-head, head-to-tail, or tail-to-tail in the 
genome, although most binding sites are found in the head-to-head orientation20. There 
are a large number of putative p53 binding sites throughout the genome, particularly in 
short and long palindromic repetitive genome elements, whose function is not known 
but speculated to participate in the trans-repression of gene targets by p5321. 
 1.1.4 Regulation of p53 – Stability and Transcriptional Activation 
 Regulation of p53 is an important part of cellular homeostasis because of the 
double-edged nature of p53. On one hand, fast activation and stability of p53 is required 
to deal with a range of genomic insults22. On the other hand, if p53 remains stable for 
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too long, the cellular aging process is engaged and cells can undergo irreversible cell 
cycle arrest and senescence23. Under normal conditions, p53 is maintained at a low 
basal level by its negative regulator and E3 ubiquitin ligase, MDM2. Polyubiquitination of 
p53 by MDM2 and MDMX leads to p53 degradation through the 26S proteasome24. 
MDM2 itself is a transcriptional target of p53, leading to a negative feedback loop where 
upon completion of p53 function, there is an abundance of MDM2 to quickly degrade 
excess p53 and return the cell to a state of regular homeostasis25,26 In the presence of 
DNA damage, hypoxia, oncogene activation, or other triggers, p53 is stabilized through 
a range of post-translational modifications (PTM), namely phosphorylation by damage 
sensors ATM and ATR at several N-terminal serine and threonine residues27. The 
stability of p53 induced by PTMs primarily serves to weaken the interaction between 
p53 and MDM2, further highlighted by the phosphorylation-dependent recruitment of 
acetyltransferases which acetylate the lysine residues in the C-terminal region in a 
mutually exclusive manner that blocks their ubiquitination28. 
 In addition to protein stability, post-translational modifications of p53 also serve a 
broader role of fine-tuning the transcriptional activation target choice by the tumor 
suppressor. As mentioned, p53 has several hundred transcriptional targets which have 
seemingly conflicting roles if all were to be activated at once, namely the competing 
pathways of cell cycle arrest and apoptosis28. For example, it has been observed that 
lower levels of p53 expression correlate with activation of cell cycle arrest genes and 
higher p53 expression leads to activation of genes associated with apoptosis29,30. This 
regulation of choice between cell cycle arrest and apoptosis by p53 stability agrees with 
the idea that apoptotic genes tend to have p53 consensus sequences which are 
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oriented in a way that requires higher p53 cooperation, and higher levels of p53 are 
required for their activation31. However, this idea is confounded by the observation that 
regardless of the expression level of p53, the p53 response elements of apoptosis 
genes are occupied by p53, meaning there must be another explanation outside of the 
increased need for cooperative binding of the apoptotic gene enhancer region. 
Additionally, it has been seen in mice that increased stability is not necessary for p53 to 
exert its tumor suppressive activities32. The same study showed that substitution of the 
seven murine lysine residues to glutamine residues (mimicking acetylation of the lysine 
residues) in the C-terminal basic domain increased transcriptional activation of p53 
targets in various tissues without a detectable increase in p53 levels32. These results 
indicate that while p53 stability and activation is important for several functions, p53 is 
still able to perform many functions independent of this stabilization and that the C-
terminal domain is a contributor to these p53 behaviors. 
 The C-terminal basic domain (CTD) is a key regulatory region for both the 
stability and function of p53. Termed the “basic domain” because of its many basic 
amino acids, allowing several post-translational modifications including phosphorylation, 
acetylation, ubiquitination, methylation, SUMOlation, NEDDylation, and PARylation27,33. 
In addition to the many modifications possible on the CTD, this domain also facilitates 
many protein-protein interactions between p53 and several binding partners including 
MDM2, MDMX, p300/CBP (responsible for ubiquitination and acetylation of the CTD), 
as well as ETS2, 53BP1, TAF1, and 14-3-3 protein27. Each of these modifications and 
protein interactions fine-tune the functionality of p53 in response to external stimuli. 
Initially thought to negatively regulate DNA binding, the CTD has been found to be a 
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second DNA binding domain for p53 where the positively charged basic amino acid 
residues contact the negatively charged phosphate backbone of DNA by means of 
electrostatic interaction10,11,20,34. This interaction facilitates rapid linear diffusion along 
double stranded DNA and has been hypothesized to assist in a “search” functionality for 
p53 to scan the genome for its consensus sequence14,15. The CTD assists the 
sequence recognition of the sequence-specific DNA binding domain (DBD) in the case 
of less-than-ideal consensus sequences, likely by providing flexibility to the protein due 
to its intrinsically disordered nature35-37. Deletion of CTD residues reduce the DNA 
binding affinity of p53 and reduce transcriptional activity of p53 targets related to cell 
cycle arrest and apoptosis37. This in turn means that the CTD is responsible for the 
regulation of a subset of p53 target genes by means of p53 response element 
recognition37,38. Furthermore, this idea was explored in vivo in a murine model where 
the final 24 amino acids of the p53 CTD were deleted, and it was observed that there 
were tissue specific transcriptional effects which indicated a regulation of target genes 
through multiple distinct mechanisms36. Specifically, it was seen that in bone marrow, 
loss of the CTD resulted in increased expression of p21 and in the thymus, loss of the 
CTD caused an increase in pro-apoptotic factors PUMA and NOXA. This suggests the 
CTD also has negative regulatory effects on transcription which is cell-type and likely 
post-translational modification-dependent. Conversely, the liver had a decrease of gene 
activation when the p53 CTD is lost, and in the spleen, loss of the p53 CTD stabilizes 
the protein, leading to increased gene activation. Therefore, clearly the regulation of p53 
transcriptional activation is multifaceted and depends not only on p53 protein stability, 
but gene target and the tissue-specific cellular context.  
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1.1.5 Transcription-independent functions of p53 
 Outside its role as a classical transcription factor, there have been numerous 
observed transcription-independent roles for p53 to assist in the maintenance of normal 
cellular homeostasis. Interestingly, p53 directly functions in several DNA repair 
pathways including nuclear excision repair, base excision repair, mismatch repair, non-
homologous end joining, and homologous recombination through use of its interaction 
with several co-factors and its sequence-independent DNA binding C-terminal basic 
domain39. Wild-type p53 also has functions in DNA replication where it has been seen to 
assist in processivity, trans-lesion synthesis, and replication restart40-43. There are cases 
where even the transcriptional activity of wild-type p53 is dispensable for activation of 
apoptosis through its localization to mitochondrial membranes and binding to Bcl-2 and 
BclxL leading to the permeabilization of the mitochondrial membrane and subsequent 
initiation of apoptosis44.  
1.2 Mutant p53 
Considering the central role p53 plays in maintaining genomic stability, it is 
sensible that any disruption of p53 transcriptional regulation would lead to significant 
contributions to human disease. Indeed, TP53 is mutated in ~50% of all human 
cancers45. Mutations in the TP53 gene have been identified at virtually every codon 
within the DNA-binding domain in cancer patients, and it is observed that ~95% of 
cancer-associated TP53 mutations occur in the central DNA binding domain46. The 
majority of TP53 mutations are missense mutations - a single point mutation in the 
coding sequence resulting in expression of a full-length mutant p53 protein with a single 
amino-acid substitution. Most often, missense mutations in p53 protein result in a loss-
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of-function phenotype, where the resulting mutant p53 protein is no longer capable of 
functioning as a transcription factor, losing its tumor suppressive capabilities when the 
second allele is either deleted or mutated. Over 70% cancers have mutant p53 protein, 
making it the single most common mutated protein in human cancers47. Roughly 95% of 
all p53 mutations cluster in the site-specific DNA binding domain, which responsible for 
the protein’s recognition of a consensus binding site required for p53 transactivation 
activity. Mutations in this region render p53 unable to activate transcription of its 
canonical targets, and such mutations are termed “loss-of-function” mutations. These 
missense mutations result in increased stability of the mutant p53 protein in cancer cells 
(but not in normal cells48) compared to the wild-type protein through unknown 
mechanism, but most likely through dysregulation of the p53-MDM2 feedback loop25. 
There is also a dominant-negative effect for loss-of-function mutant p53 whereby 
introduction of a p53 mutant protein inhibits the ability of any remaining wild-type p53 to 
transactivate tumor suppressive gene targets49. This was highlighted in early studies of 
p53 where it was reported that p53 could cooperate with ras to transform fibroblasts – it 
was later clarified that the p53 studied in these lines was loss-of-function mutant p53 
exerting dominant negative effects on the existing wild-type p53 expression, allowing for 
normal fibroblast cells to be transformed by ras1,50. Additionally, in cells which express 
one mutant p53 allele there is often a loss-of-heterozygosity where the remaining wild-
type p53-expressing allele is spontaneously deleted, leaving only mutant p53 
expression in those cells51. Two main classes of mutant p53 have been noted, 
mutations which alter the overall structure of the protein, called conformational mutants, 
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and mutations which directly alter the residues responsible for DNA binding in the 
protein, DNA contact mutants.  
The most frequent somatic mutations are highly selected for and six codons 
observed to be mutated more than any other (R175, G245, R248, R249, R273, R282) 
have been named “hotspot” mutations45. Mutations in p53 are broadly classed as either 
conformational mutants impacting the overall structure of mutant p53 (for example, 
R175H, G245S, R249S, R282W) – or DNA contact mutants, impairing site-specific DNA 
binding at the amino acid residues that contact the p53 consensus sequence (for 
example, R248Q/W, R273H)52. While these hotspot mutants are observed generally 
across all cancers, specific cancer sites can exhibit differences in the frequency of p53 
mutation, particularly as it relates to the relative mutagenicity as well as timing of disease 
progression53. For example, p53 is most often mutated in breast, bone, brain, and other 
soft tissues, while it is least commonly observed in leukemia, stomach, or colorectal 
cancers53. In terms of disease progression, p53 can be an early- or late-stage event 
depending on the cancer type, and in the case of prostate cancer, p53 mutations are 
rarely seen in hormone-responsive prostate cancer, and more often seen in metastatic 
hormone-resistant prostate cancer53,54. 
It has also been observed that mutations at particular amino acid residues within 
p53 (often hotspots but not exclusively) confer pro-survival and oncogenic behaviors 
including increased tumor growth, genomic instability, invasion, chemo resistance, and 
alter diverse proteome and metabolic pathways, which have been termed “gain-of-
function” mutations55-66. These gain-of-function mutations are known to share some 
properties across all mutant p53 while also having some distinct characteristics 
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depending on the mutation, and therefore it has been described that different GOF mtp53 
proteins can have unique oncogenic properties46,67-69. Gain-of-function p53 mutations 
have been observed to result in a worse prognosis in both genetically engineered mice, 
and in a Chinese cohort of triple-negative breast cancer patients70,71, indicating that the 
physiological impact of the observed gained functions are a significant and pressing issue 
to understand further. 
We do not understand the mechanism of gain-of-function mtp53 and very few 
studies have examined the gain-of-function contributions of the C-terminal basic 
domain. When considering the prevalence of mutant p53 in cancer and the added 
danger of gain-of-function mutant p53, it is important to pursue a deeper understanding 
Figure 1.2 Model for mtp53-PARP-MCM axis on replicating DNA in MDA-MB-468 
cells 
A) Mtp53 R273H (green) increases the localization of PARP1 (red) and MCM2-7 (blue) 
on replicating DNA (i), where in the presence of damage they help facilitate aberrant 
DNA repair (ii), allowing for cell survival and promoting tumorigenesis (iii). B) In cells 
with high expression of PARP1 and mtp53, combination treatment with temozolomide 
(blue star) and talazoparib (yellow cage), induces PARP trapping on chromatin, 
increasing unrepaired DNA (ii) and promoting cell death (iii). Adapted from Xiao, 2020. 
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of each domain’s contribution to tumorigenesis and cancer progression. Herein, we 
explore gain-of-function mutant p53 through the mtp53-PARP-MCM axis, our observed 
axis in which mutant p53 R273H increases chromatin-bound PARP1 and the MCM2-7 
helicase complex58. We evaluate one of the most common mutant proteins, the R273H 
DNA contact mutant protein, where the axis is well established in MDA-MB-468 cells 
(Fig. 1.2)56,58 and assess the contribution of the C-terminal basic domain to the 
participation of R273H in this axis. We focus on the C-terminal domain as a potential 
mediator of R273H non-specific DNA binding because the R273H contact mutation 
leads to a loss of site-specific DNA binding, but R273H is still seen very stably bound to 
chromatin56,58. We also examine two less commonly seen p53 mutants, P223L and 
V274F, to understand if these mutants also lead to a mtp53-PARP-MCM axis.  
1.3 Roles of p53 and PARP in DNA replication 
1.3.1 A summary of DNA replication 
 The faithful replication of DNA is central to all living organisms and is therefore a 
tightly regulated and controlled sequence of events72-74. The first regulatory event is 
through cell cycle control, where progression from G1 to S phase is closely monitored 
and dependent on the production of cyclins and cyclin-dependent kinases. The 
beginning of S-phase is marked by the assembly of several replication factors into a 
replisome, the functional unit which will provide processivity throughout DNA replication. 
Some of the key steps in replisome assembly include the recruitment and loading of 
PCNA, ORC1-6, and the replicative helicase made up of MCM2-7 onto chromatin at 
replication origins75-77. In yeast, these replication origins have discrete sequences and 
can be easily predicted72. However, in higher order eukaryotes, no such origin 
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sequence is known to exist, and the clear definition of a replication origin remains a 
mystery72,74,75. Once PCNA, ORC1-6, and the MCM2-7 complex are loaded onto 
chromatin, CDC7 will phosphorylate the helicase in a process known as origin licensing. 
Origin licensing allows for each origin to only initiate replication once per cell cycle, 
preserving genomic integrity and maintaining total chromosomal DNA content 
throughout the cell cycle78. The DNA replication fork is fired bi-directionally and 
proceeds to replicate DNA through the use of several polymerases to facilitate leading 
and lagging strand synthesis. Due to the directionality of DNA, the synthesis of DNA 
occurs in the 5’->3’ direction and therefore multiple types of synthesis are required to 
replicate both strands simultaneously. The most straightforward synthesis is leading 
strand synthesis where polymerase epsilon rapidly incorporates nucleotides in the 5’->3’ 
direction as the fork also travels in that direction74. Lagging strand synthesis is the 
solution to the problem of needing to replicate DNA on a strand that is oriented in the 3’-
>5’ direction. Polymerase alpha primase functions in lagging strand synthesis by 
generating small sets of RNA nucleotide primers so that replication can still occur in 
short bursts in the 5’->3’ direction by polymerase delta. These short RNA-DNA hybrids 
generated on the lagging strand are famously known as Okazaki fragments. Upon 
polymerase delta synthesizing a portion of the lagging strand from an Okazaki fragment 
template, there is a resulting gap or nick in the DNA where the newly synthesized strand 
runs into the next Okazaki fragment79. The resolution of these Okazaki fragment 
intermediates occurs very quickly through FEN1 , which removes RNA intermediates 
and generates a nick which is readily repaired by XRCC1 and ligated by Lig180.  
1.3.2 PARP1 and DNA replication 
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 Recently, it has come under consideration that poly-ADP-ribose polymerase 1 
(PARP1) plays a major role in the recognition of unligated Okazaki fragments81. PARP1 
is the leading member of a family of polymerases which catalyze the addition of chains 
of ADP-ribose which typically serve to recruit DNA repair proteins, for both single- and 
double- strand DNA breaks82. However, in the case of unligated Okazaki fragments, 
they functionally appear as single strand breaks and PARP1 acts to resolve this stress 
and ensure efficient replication. In fact, the majority of poly-ADP-ribosylation in cells 
occurs during DNA replication as a means of recruiting XRCC1 to unligated Okazaki 
fragments. This is highlighted by data which shows deficiencies in either XRCC1 or 
FEN1 lead to rapid cell death when combined with a PARP inhibitor81.  
The timing and completion of DNA replication in S-phase relies on a number of 
factors, namely the combination of replication fork speed and the resolution of DNA 
repair and complex replication intermediates, termed processivity. There is a 
mechanism in place to ensure the timely replication of the genome where replication 
processivity is sensed through an unknown mechanism, and if processivity drops, there 
is a concomitant increase in the amount of replication origins which are fired and 
used72,75,83-85. This dynamic balance offsets any speed changes by a similar concept to 
the saying “many hands make light work”. However, when PARP1 is inhibited, DNA 
replication fork speed increases, likely arising from an inability for cells to sense 
unligated Okazaki fragments on the lagging strand of DNA replication. Subsequently, as 
a result of inhibited PARP1, lack of detection of fault lagging strand synthesis, and 
increased replication fork speed, the level of genomic instability in cells increases86,87.  
1.3.3 p53 in DNA replication: 
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 A role for wild-type p53 has emerged in the DNA replication processivity, the 
efficient resolution of DNA stress, and maintenance of DNA replication homeostasis. 
When replication fork stalling is initiated by treating cells with hydroxyurea or mitomycin 
C, wild-type p53 binds directly to replicating DNA and recruits a chromatin modifier, 
MLL343.  MLL3 is known to open chromatin near stalled replication forks and allow for 
recruitment of MRE11, an important step in DNA replication fork stability and restart88. 
Through a second mechanism, wild-type p53 suppresses the use of RAD52-mediated 
DNA repair, which is a more error-prone and mutagenic repair pathway utilizing 
polymerase theta43,89. Furthermore, it has been observed that in the presence of UV-
irradiation which generates bulky thymidine adducts, p53 induces polymerase eta and 
cells undergo trans-lesion synthesis thus avoiding replication fork stalling42. As another 
means of damage tolerance, p53 also induces polymerase iota to assist in trans-lesion 
synthesis90. In the absence of DNA damage, it has been observed that wild-type p53 is 
transcriptionally active during S-phase and facilitates DNA replication processivity 
through induction of targets which modify chromatin, such as was observed with 
MDM241. These studies point to wild-type p53 being an active player in maintaining 
DNA replication homeostasis, and lead to questions regarding what happens when p53 
becomes mutated. Of particular interest, as the stability of mutant p53 increases and its 
transcriptional functions falter, perhaps the transcription-independent DNA replication 
functions remain and mutant p53 aids in DNA replication processivity and genomic 




















2.1 Cell culture 
The DU145 cell line was a generous gift from Dr. Adrie von Bokhoven91 and later 
purchased from ATCC. The HCT116 p53-/- cell line was a generous gift from Bert 
Vogelstein92. The H1299 cell line was purchased from ATCC. The MDA-MB-468 cell 
line was purchased from ATCC. CRISPR/Cas9 modifications to the MDA-MB-468 cell 
line to generate R273H∆381-388, R273H∆347-393, and R273Hfs387 clones were 
performed by Dr. Jill Bargonetti and characterized by Viola Ellison, Gu Xiao, George 
Annor, and Devon Lundine as described previously55. Cell lines were cultured in a 
humidified incubator at 37°C and 5% CO2 using recommended media by the American 
Tissue Culture Collection - DMEM in the case of DU145, and MDA-MB-468 (and 
associated CRISPR lines), McCoy’s 5A media (Gibco) in the case of HCT116 p53-/- and 
RPMI media in the case of H1299 cells - supplemented with 10% fetal bovine serum 
(Gemini), 50U/mL penicillin, and 50ug/mL streptomycin (Mediatech). Cell lines were 
routinely submitted for authentication and mycoplasma testing (Genetica). 
 
2.2 Whole cell lysis and immunoblotting 
Cells were harvested at 1100 rpm for 5 min at 4°C on Sorvall benchtop centrifuge. Cells 
were washed three times with ice-cold PBS and resuspended in RIPA buffer (0.1% 
SDS, 1% IGEPAL NP-40, 0.5% Deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 50 mM Tris-Cl pH 8.0, 1mM PMSF, 8.5 µg/ml Aprotinin, 2 µg/ml Leupeptin and 
phosphatase inhibitor cocktail). The cell suspension was incubated on ice for 30 min to 
lyse the cells, vortexing every 5 min. Additional sonication of lysate for 3 times for 30 
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sec pulses/ 30 sec rest on ice at 98% amplitude was done after the incubation. Samples 
were centrifuged at 13,000 rpm for 30 min at 4°C, supernatant collected, and protein 
quantified via Bradford assay. Cell extracts were run on SDS-PAGE to separate 
samples followed by electro-transfer onto polyvinylidene fluoride (PVDF) membrane 
(GE). The membrane was blocked with 5% non-fat milk (Bio-Rad) in 1X PBS-0.1% 
Tween-20 followed by incubation with primary antibody overnight at 4°C. The 
membrane was washed 3x with either 1X PBS-0.1% Tween-20 and incubated 
with cy5/cy3 secondary antibody for 1hr at room temperature. The signal was 
detected with the Typhoon FLA 7000 laser scanner (GE Healthcare). Quantification of 
western blot signal was done by densitometry using ImageJ.  
 
2.3 Mitochondrial activity assay (MTT) 
Cells were seeded into 12-well plates at a density of 70,000 cells/well with DMEM 10% 
FBS overnight before drug treatment of DMSO (vehicle control), Temozolomide (1mM) 
and/or Talazoparib (10uM) in DMEM 5% FBS. After the indicated treatment time, MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) was added to each well 
(10% v/v) and cells were incubated at 37oC for 45 minutes. After incubation, cells were 
lysed in acidified isopropanol and absorbance values were measured on a plate reader. 
 
2.4 Transient transfection of phoenix packaging cells  
Phoenix packaging cells were plated at a density of 5x106 cells in a 10cm2 tissue culture 
dish and incubated overnight. Media was then changed to 9 ml of complete DMEM 
media supplemented with 25 μM chloroquine. A transfection mixture was generated by 
19 
 
adding 20 μg MLP plasmid (with/without shRNA) and 5 μg of helper plasmid to a 
solution of 2 M CaCl2 in 0.01 M HEPES pH 5.5 in sterile water plus 2X BBS (50 mM 
BES, 280 mM NaCl, 1.5 mM Na2HPO4 at pH 6.95) dropwise while bubbling the 
solution. This mixture was then added to the packaging cells and incubated overnight. 
The following day, media was replaced on packaging cells twice with at least 8hr 
between intervention and incubated overnight. The next day, media containing virus 
was collected every 5 hrs and replaced with fresh media. Viral containing media were 
filtered through 0.45 μm syringe filter and used immediately or stored at -80ºC.  
 
2.5 Retroviral-mediated gene transfer  
Cells were seeded 30% confluency one day before infection into 10 cm plate. On the 
day of infection, viral containing media were diluted (1:2 ratio) with fresh media and 
combined with 10 μg/ml polybrene before adding to the targeting cells (7 ml per 10 cm 
plate). The plate was then incubated for 5 hrs at 37°C. Replace with fresh infection 
cocktail and repeat the incubation for another 5 hrs. Remove the infection cocktail and 
replace with fresh media. Cells were grown overnight before being split into 5 μg/ml of 
Puromycin containing media for selection over 7 days.  
 
2.6 Sequence analysis and verification of CRISPR mutagenesis 
Sanger sequencing was done from PCR amplified cDNA from total RNA purified from 
isolated MDA-MB-468 CRISPR-modified clones (Genewiz). 5 μg of RNA prepared using 
the Qiagen RNeasy kit was used for each cDNA synthesis reaction (Applied Biosystems 
High-Capacity cDNA Reverse Transcription Kit), and the TP53 gene was subsequently 
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PCR amplified (Phusion polymerase; New England Biolabs) using 5% of the cDNA 
synthesis product as template and TP53 gene primers Exon 9–10 Forward and Exon 
10–11 Reverse. Sequencing data was generated from cDNA produced from three 
independent RNA preparations. Sequence analysis of the entire TP53 gene within 
parental MDA-MB-468 and MDA-MB-468 CRISPR-Cas9 CTD sgRNA clones C11 and 
C14 was performed by PCR amplification of the TP53 gene from cDNA using TP53 
primers 134–153 5′ Forward (maps to nucleotides 134–153 within Exon1) and 1422–
1441 3′ Reverse (maps to nucleotides 1422–1441 within Exon 11). The following 
primers were used for sequencing TP53 PCR products: Exon 1 Forward 5′ 
GACACGCTTCCCTGGATT G; Exon 4 Reverse 5′GGGACAGAACGTTGTTTTCAGG; 
Exon 5 Reverse 5′ TGTGGAATCAACCCACAGC; Exon 8 Forward 5′ ACA GCA CAT 
GAC GGA GGT TGT; Exon 8 Reverse 5′ CTTGCGGAGATTCTCTTCCTC; Exon 11 
Reverse 5′ AGCAAGGGTTCAAAGACCCA. 
 
2.7 DNA fiber assay 
Cells were treated with IdU (50uM) for 10 minutes followed by 2 washes in warm PBS, 
then treated with CldU (50uM) for 30 minutes. Cells were washed twice in PBS again 
and removed from the plate by trypsinization. Cells were centrifuged at 1200 rpm for 5 
minutes at 4 degrees and trypsin was removed. Cells were resuspended in PBS at a 
density of approximately 1x106 cells/mL. Cells are then spotted onto a clean microscope 
slide at a volume of 2 uL and lysed in 7uL lysis buffer (0.5% SDS in 200mM Tris-HCl pH 
7.4, 50mM EDTA) with pipetting several times for 6 minutes at room temperature. Slides 
are then tilted at an angle of roughly 30 degrees and the lysis solution is allowed to run 
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down the slide. Slides were air dried and were then fixed in a solution (75% methanol, 
25% glacial acetic acid) 4 minutes at room temperature in a Coplin jar. Slides were 
allowed to air dry and then stored overnight at 4C. The following day, the slides are 
treated with 2.5N HCl for 30 minutes at room temperature in a Coplin jar. Following 3 
washes with PBS in a Coplin jar, slides were placed in blocking solution (10% goat 
serum in 0.1% Triton X-100 in PBS for 1 hour at room temperature. Following blocking, 
slides were incubated 1 hour at room temperature with primary antibodies targeting IdU 
and CldU at a dilution of 1:100 in blocking buffer and kept in the dark. Following 3 
washes with PBS, slides were incubated with secondary antibodies for 1 hour at room 
temperature at a dilution of 1:350 in blocking solution. Following 3 additional washes 
with PBS, slides were air dried in the dark, then mounted with 70uL Prolong Gold 
mounting media (Invitrogen) and a coverslip was added. Slides were dried overnight 
and visualized on a confocal microscope with a 60X objective lens. All subsequent 
analyses were done on NIS Elements, ImageJ, and GraphPad Prism. 
 
2.8 Flow cytometry 
Sub-confluent cells were synchronized with aphidicolin (5uM) for 24 hours and released 
into fresh media. Cells were harvested at selected time points by trypsinization and 
spinning in a tabletop bucket centrifuge (1500 rpm, 5 min). Cells were washed and 
resuspended in ice cold PBS at a density of 2x106 cells/mL. Cells are fixed by adding 
cell suspension dropwise into a solution of 70% ethanol while vortexing continuously. 
Cells were stored at -20C overnight and then spun down and resuspended in 500uL 
propidium iodide staining solution (0.1% PBS-TritonX100, 200ug/mL RNAseA, 60uM 
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propidium iodide), filtered through a nylon mesh into a polystyrene tube, and analyzed 
on a flow cytometer. Analysis was done with FlowJo 10.7 and GraphPad Prism. 
 
2.9 Proximity ligation assay 
Cells are seeded on a glass bottom 12 well tissue culture plate (Mat-Tek). Subconfluent 
cells are washed 3 times with ice cold PBS for 2 min, followed by fixation in 4% 
formaldehyde in PBS for 15 min at room temperature with gentle agitation. Cells are 
washed an additional 3 times with PBS 2 min per wash, followed by permeabilization in 
0.5% TritonX-100 in PBS for 10 min at room temperature. After another 3 PBS washes, 
cells are blocked with PLA blocking solution (Sigma) 30 min at 37C. Cells are then 
treated with primary antibody overnight in a humidified container at room temperature. 
The following day, cells are washed 3 times with PLA buffer A (Sigma) 5 min with gentle 
agitation at room temperature. Secondary PLA probes are added to cells for 1 hour at 
37C in a humidified chamber. Following an additional 2 washes with PLA buffer A, cells 
are treated with Ligase for 30 min at 37C in a humidified chamber, and then washed an 
additional 2 times in buffer A for 2 min each. Next, cells undergo a PLA amplification 
reaction (Sigma) for 100 min at 37C in a humidified chamber. Cells are then washed 
with PLA buffer B (Sigma) 2 times for 10 min at room temperature, followed by a final 
wash with 1% buffer B in H2O, and mounting media with DAPI is added to the cells 
(Sigma) prior to imaging on a confocal microscope. Images were analyzed with ImageJ, 





Cells are lysed in NP40 buffer (50mM Tris pH 8.0, 5mM EDTA, 150mM NaCl, 0.5% NP-
40) and passed through a 211/2 gauge needle 10 times every 10 min at 4C for a total of 
30 min. Lysates were centrifuged at 13,200 rpm on a table-top microcentrifuge for 15 
minutes and supernatant transferred to a new tube. After protein quantification by 
Bradford assay, 1mg total protein is pre-cleared by adding 1ug mouse IgG and 30uL of 
protein A/G plus agarose beads and rotating at 4C for 30 min. Beads are spun down at 
4000 rpm for 1 min and supernatant moved to a new tube where pull-down antibody-
conjugated agarose beads are added and rotated at 4C overnight. The following day, 
beads are spun down at 4000 rpm for 1 min and washed with 1mL wash buffer (50mM 
Tris pH 8.0, 5mM EDTA, 150mM NaCl) four times. After the last spin, 1x sample buffer 
with 50mM DTT is added on top of the beads, which are boiled at 70C for 10 mins, the 
tube is spun down at 13,200 rpm for 1 min, and the supernatant is moved to a new tube, 
ready to be loaded onto SDS-PAGE. 
 
2.11 Isolation of Proteins on Nascent DNA (iPOND) 
A total of 1 × 108 cells were plated one day before 5-ethynyl-2´-deoxyuridine (EdU) 
treatment. Cells were incubated with 10 μM EdU for 45 minutes at 37oC. Cells were 
fixed with 10 mL 0.5% formaldehyde in PBS for 20 minutes and quenched with 1 mL 
1.25M glycine. Cells were permeabilized with 0.25% Triton X-100 in PBS for 30 minutes 
followed by a click chemistry reaction. The click reaction contained 2 mM copper 
sulfate, 10 μM biotin-azide, and 10 mM sodium ascorbate added to PBS for 1.5 hours at 
room temperature with rotation. Cells were then lysed in RIPA buffer on ice for 30 
minutes, with vortexing every 5 minutes. Additional sonication of lysate (18× on ice for 
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30 seconds on/off at 98% amplitude) was done after the incubation. Samples were 
centrifuged at 13,000 rpm for 30 minutes at 4°C. Biotin-EdU–labeled DNA was 
incubated with streptavidin–agarose beads at 4°C for 20 hours. The beads were 
washed with RIPA buffer three times and proteins bound to nascent DNA were eluted 
by incubating in 2 × SDS Laemmli sample buffer containing 0.2 M dithiothreitol (DTT) for 
25 minutes at 95°C. Samples were then run on a gel as described in the immunoblotting 
section. 
 
2.12 Plasmid constructs, site-directed mutagenesis, and plasmid sequence 
validation 
The NEBasechanger platform was used to design primers to introduce point mutations 
within the DNA binding domain of pLNCX plasmids expressing wtp53 6KR or wtp53 
6KQ (generously gifted from Dr. Carol Prives)38. For generation of the R273H mutation, 
the primer sequences are Forward: TTTGAGGTGCaTGTTTGTGCC and 
Reverse: GCTGTTCCGTCCCAGTAG. Mutagenic PCR was carried out with the Q5 
mutagenesis kit (NEB) at the primer-specific recommended annealing temperature of 
64°C. After confirming PCR amplification by agarose gel electrophoresis, a kinase-
ligase-Dpn1 (NEB) reaction was done prior to transforming DH5a competent cells. 
Clones were inoculated in LB+ampicillin (50ug/mL) media and plasmids were purified 
with the Qiagen miniprep/midiprep kit and sent for sequencing (Genewiz) using a 
p53 Exon 8 forward primer (5’ ACAGCACATGACGGAGGTTGT). Sequences were 
compared to TP53 cDNA using the Benchling platform. The pCMV-FLAGp53∆24 
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plasmids (including wtp53, wtp53∆24, R175H, R175H∆24, R248Q, R248Q∆24, R273H, 
R273H∆24) were a generous gift from Dr. Jim Manfredi37. 
 
2.13 Mammalian cell transfections 
Plasmids were transfected into HCT116 p53-/- and H1299 cells using lipofectamine 2000 
(Thermofisher) and Nucleofection (Thermofisher Neon). For lipofectamine, cells were 
seeded at 50-60% confluency in McCoy’s 5A media + 10% FBS without antibiotics 24hr 
before transfection. The amount of plasmid DNA and lipofectamine were optimized 
based on the protocol from Thermofisher. On the day of transfection, plasmid DNA and 
lipofectamine were diluted in Opti-MEM (Thermofisher) and incubated for 20min at room 
temperature after mixing. The DNA-lipofectamine complex was added to cells and 
incubated for 4hr before changing media to McCoy’s 5A media + 10% FBS with 
antibiotics, and harvested 24hr after transfection by scraping. 
2.14 Chromatin fractionation 
Localization of mtp53 proteins to chromatin was assessed using an abridged version of 
the Chromatin Fractionation Assay as described by Ellison et al, 2021. Cells were 
harvested 24hr post transfection as dictated by experimental conditions by scraping, 
pelleted and washed with ice-cold PBS as described above, and then resuspended in 
Buffer A (10mM HEPES, 10mM KCl, 1.5mM MgCl2, 300mM Sucrose, 1mM DTT, 10% 
Glycerol, 0.1mM PMSF, 1μg/ml Leupeptin, and 2μg/ml Aprotinin) with 0.1% Triton X-
100 in a volume based on the pellet size. The resuspended pellet was centrifuged at 
4000 rpm for 5 min after incubating on ice for 5min. The pellet (nuclei) was saved, the 
supernatant was spun at 13000 rpm for 5 min and subsequent supernatant saved as S1 
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cytosolic fraction. The nuclei from each sample were washed twice in Buffer A 
and further lysed in Buffer B (3mM EDTA, 0.2mM EGTA, 1mM DTT, 0.1mM PMSF, 
1μg/ml Leupeptin, and 2μg/ml Aprotinin) on ice for 30 min with vortexing every 5 min. 
The chromatin for each sample was separated from the nuclear lysate (S2) by 
centrifugation for 4 min at 4000 rpm at 4℃, washed in Buffer B and collected by 
centrifugation as described above.  The chromatin pellet was resuspended in Buffer 
B and sonicated on ice (3 cycles, 98% power, 30 seconds per cycle) and saved as P3. 
The protein concentrations were measured using the Bradford assay. 
 
2.15 Statistical analysis 
Statistical analyses were conducted in Excel or Graphpad Prism 9. Results are 
expressed as mean + SEM. Statistical significance for hypothesis testing was performed 
by two-tailed Student's t-test of unknown variance. The following format was used to 
assign significance based on P-value: * represents a p-value ≤ 0.05, ** represents a p-













Exploring mutant p53 P223L and V274F in PARP-
inhibitor sensitivity of DU145 prostate cancer 





Prostate cancer is currently the most common cancer developed in males globally 
and the second highest cause of cancer-related deaths in men in the United States93. 
Most primary prostate cancers can be treated with androgen deprivation therapy (ADT), 
starving the cancer of necessary growth hormones, leading the cancer cells to undergo 
growth arrest94. However, prostate cancer can advance to become castration-resistant, 
unable to be treated by ADT, whereupon 90% of such castration-resistant prostate 
cancers (CRPC) result in metastases95. To date, CRPC is recognized as an incurable, 
and ultimately fatal disease96. It is therefore critical to advance the understanding of the 
underlying mechanisms of the advancement of primary prostate cancer to CRPC and 
identify potential therapies to this incurable condition. 
Recently, PARP inhibitors have been recognized to have a broad potential in cancer 
therapeutics97. Many of the current clinical trials involving PARP inhibitors utilize defunct 
pathways in homologous recombination, driven by mutations in BRCA1, to induce 
synthetic lethality in cancer cells by treating trial participants with PARP inhibitors, such 
as rucaparib, olaparib, or talazoparib98. There is some evidence however, that PARP 
inhibitors may be effective in a wider range of patients, such as those with deficiencies in 
Rad51, or even p53, where mutations lead to deficiencies in homologous recombination, 
theoretically rendering these cells sensitive to PARP inhibitor treatment82. Our group has 
previously published that in the triple negative breast cancer cell line MDA-MB-468 
(expressing mtp53 R273H), there is a mtp53-dependent increase of chromatin-bound 
PARP1 which can be exploited by treatment of cells with a combination treatment with 
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DNA alkylating agent temozolomide, and PARP inhibitor/trapping agent, talazoparib, to 
induce PARP trapping and ultimately apoptosis99. 
While primary prostate cancer has a notably low occurrence of mtp53 (~10%), it has 
been observed that greater than 50% of CRPC harbor mtp53 protein100. Unlike the 
common observation of hotspot mutations of p53, the frequency of particular p53 
mutations in prostate cancer is still unclear, with p53 mutations being a late-stage event 
in the development of metastatic prostate cancer101. The mtp53 proteins present in the 
CRPC cell line DU145 (P223L and V274F), while not traditional hotspot mutations, have 
been observed to provide a selective growth advantage in DU145, with cell viability 
dropping sharply upon transient depletion of mtp5365. This indicates that these mutant 
alleles harbor some gain-of-function pro-survival activity, which could be potentially 
targeted for therapeutic treatment. Therefore, we investigated whether these mtp53 
proteins increase PARP localization to chromatin and provide sensitivity to combination 




3.2.1 DU145 cells exhibit enhanced lethality with combination treatment of PARP 
inhibition and DNA damage 
We asked if the androgen-independent cell line DU145 could be killed with a 
combination of the DNA alkylating agent temozolomide, and the PARP inhibitor and 
trapping agent, talazoparib. We observed significant lethality by mitochondrial activity 
assay under dual drug treatment but not with single drug treatments (Fig. 3.1 A). We 
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also saw that in DU145 cells treated with temozolomide and talazoparib there was 
caspase 3/7 cleavage, indicative of activation of apoptosis (Fig. 3.1 B). 
 
3.2.2 PARP-inhibitor induced lethality is partially rescued by growing cells at 32oC 
We explored the possibility that the exhibited sensitivity to combination treatment 
with temozolomide and talazoparib could be driven by gain-of-function mutant p53 
present in these cells. Of particular interest, the P223L allele has been reported to be 
temperature sensitive, reverting to a wild-type like conformation, when maintained at 
Figure 3.1 DU145 cells are sensitive to combination DNA damage and PARP 
inhibition. 
A) DU145 prostate cancer cells were treated with DMSO (Vehicle control), temozolomide 
(1mM), talazoparib (10uM), or a combination of temozolomide (1mM) and talazoparib 
(10uM) for 48 hours. Cells were incubated with MTT reagent and mitochondrial activity was 
measured by spectrophotometer. Based on 3 independent biological replicates, 
***p<0.001. B) DU145 cells were treated with DMSO or temozolomide (1mM) and 
talazoparib (10uM) for 4 hours and stained for cleaved caspase 3 and 7 followed by live 
cell imaging. Representative images from 3 independent biological replicates. 
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32oC, capable of activating transcriptional targets in a reporter construct model102. To 
test this temperature sensitivity, we plated DU145 cells at 37oC allowing them to anchor 
overnight, and then shifted the temperature to 32oC and evaluated the expression of the 
well-characterized p53-target proteins p21 and MDM2. We observed at 32oC, there was 
a robust increase in both p21 and MDM2, while the level of p53 remained stable (Fig. 
3.2 A). We then treated the temperature-shifted DU145 cells with a combination of 
temozolomide and talazoparib and observed that cells grown at 32oC experience a 
partial rescue of lethality compared to DU145 grown at 37oC (Fig. 3.2 B).  
 
 
Figure 3.2 Sensitivity of DU145 to DNA damage and PARP inhibition is partially 
rescued at 32oC.  
A) Representative whole cell lysate and western blot of DU145 grown at 37oC and 
32oC. Actin is used as a loading control. B) DU145 was grown at 37oC and 32oC and 
treated with DMSO (Vehicle control), temozolomide (1mM), talazoparib (10uM), or a 
combination of temozolomide (1mM) and talazoparib (10uM) for 48 hours. Cells were 
incubated with MTT reagent and mitochondrial activity was measured by 
spectrophotometer. Based on 3 independent replicates, **p<0.01. 
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3.2.3 Mutant p53 P223L and V274F do not contribute to enhanced lethality in 
DU145 cells 
 To further interrogate the role of p53 in the enhanced lethality of treatment with 
temozolomide and talazoparib on DU145, we treated parental DU145 cells with siRNA 
targeting p53 (Fig. 3.3 A) and we also generated a DU145 cell line stably expressing 
shRNA targeting p53 (Fig. 3.3 C). We hypothesized that gain-of-function p53 was 
sensitizing DU145 to combination treatment and expected a partial or complete rescue 
in DU145 at either temperature when knocking down p53. What we observed however, 
was that DU145 experienced the same level of lethality in the presence or reduction of 
mutant p53 both in the context of siRNA and shRNA (Fig. 3.3 B and D, respectively). 
The previously observed lethality in MDA-MB-468 cells containing mtp53 R273H was 
driven by increased PARP trapping induced in part by the upregulation of PARP1 on 
chromatin by mtp53 R273H. Therefore, we examined chromatin-bound mtp53 and 
PARP1 in DU145 cells with and without expression of p53-targeting shRNA. We did not 
observe reduction in chromatin bound PARP1 when the P223L and V274F mtp53 in 
DU145 cells was depleted (Fig. 3.4). These data indicate that in DU145 cells wild-type 
p53 function with these specific mutant p53 alleles, P223L and V274F, blocks sensitivity 
to treatment at 32oC but does not contribute to the sensitivity of PARP inhibition at 37oC. 
As such, P223L and V274F mtp53 do not appear to possess the same increased 




Figure 3.3 DU145 sensitivity to combination DNA damage and PARP 
inhibition does not depend on mutant p53.  
A) Representative western blot following treatment of DU145 cells siRNA targeting 
p53 (SmartPool) for 24 hours using Lipofectamine2000 transfection reagents 
(Thermofisher). Actin is used as a loading control. B) DU145 cells were examined 
for mitochondrial activity following treatment with siRNA to p53, and either DMSO 
or a combination of temozolomide (1mM) and talazoparib (10uM) for 24 hours at 
37oC; ns - p>0.05. Based on two independent biological replicates C) 
Representative western blot depicting DU145 stably expressing either MLP empty 
vector or MLP.shp53. Actin is used as a control. D) DU145 cells stably expressing 
MLP empty vector or MLP.shp53 were examined for mitochondrial activity 
following treatment with either DMSO or a combination of temozolomide (1mM) 
and talazoparib (10uM) for 24 hours at 37oC; ns = p>0.05. Based on three 




Figure 3.4 Mutant p53 in DU145 does not alter chromatin-bound PARP1.  
A) Representative chromatin fractionation of DU145 cells stably expressing either MLP 
empty vector (EV) or MLP.shp53. S1 – Cytosolic fraction; S2 – Nuclear soluble fraction; 
P3 – Chromatin insoluble fraction. Actin is used as a cytosolic fraction loading control 






In this study, the gain-of-function mtp53 proteins in DU145 were explored as drivers 
of sensitivity to combination DNA alkylation and PARP inhibition treatment with 
temozolomide and talazoparib, respectively. We showed that the temperature-sensitive 
allele of mtp53 present in DU145 (P223L) was functionally wild-type at the permissive 
temperature, marked by higher protein levels of MDM2 and p21, two well-known 
transcriptional targets of wild-type p53. The DU145 cells exhibit sensitivity to dual 
treatment with temozolomide and talazoparib, and the observed sensitivity was 
dependent on loss-of function of mutant p53. This was clear as the restoration of p53 
transcriptional activity blocked combination temozolomide and talazoparib-induced cell 
death. Importantly, depletion of mutant p53 did not decrease sensitivity to cominbination 
treatment which demonstrates that P223L and V274F are not functionally increasing 
PARPi sensitivity. These observations suggest the possibility that wild-type p53 is 
providing protection for DU145 at 32oC, through either cell cycle regulation or modulation 
of DNA repair pathway choice. Indeed, we see a similar response in colon cancer cells103. 
Conversely, loss of wild-type p53 in cells has been shown to increase homologous 
recombination rates and reduce PARP inhibitor sensitivity39. More work will need to be 
done to better understand the mechanism of DU145 PARP inhibitor sensitivity, but this 
study was able to eliminate the contribution of gain-of-function mutant p53 alleles P223L 
and V274F as drivers of the exhibited enhanced lethality and subsequent partial rescue 
at 32oC. An important follow-up experiment to perform would be to evaluate the effect of 
temperature alone on DU145 in under treatment with temozolomide and talazoparib in 
the absence of p53. This could be accomplished by examining the mitochondrial activity 
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of sip53- or shp53-treated DU145 at 37oC and 32oC following combination temozolomide 
and talazoparib treatment. Additionally, while it is clear that the wild-type p53 in DU145 
at 32oC leads to expression of p21, other targets like BAX and PUMA could be assessed 
as a proxy of apoptosis induction, or monitoring γ.H2AX as a readout of sustained DNA 
damage, to further characterize wild-type p53 behavior in the context of combination 
temozolomide and talazoparib treatment. Results from these follow-up experiments 
would provide a clearer understanding of whether wild-type p53 is providing protection to 
cells under combination treatment and begin to address the mechanism of protection, or 
whether there is a direct temperature effect resulting in less cell death. This study was 
performed in the context of prostate cancer, where the mutant p53 hotspots are not as 
prevalent as in other cancers104. We examined the P223L and V274F mutations as 
potentially having a mtp53-PARP-MCM axis, as we saw in R273H-containing breast 
cancer cells, but it is not clear that even if R273H were introduced into prostate cancer 
cells, the same axis would persist. Different levels of PARP expression may influence the 
gained function of mtp53 R273H and would likely alter the response to PARP 
inhibition/trapping as well. In the future, we could examine P223L and V274F in a context 
which has high PARP expression, such as some breast cancer models where PARP 















Mutant p53 R273H C-terminal domain in MDA-







Our group recently observed that mtp53 R273H has a transcription-independent 
gained function by increasing the chromatin localization of DNA replication and repair 
factors MCM2-7, PCNA, and PARP158,60. We also observed direct interaction between 
R273H and replicating DNA56 and others have observed that R273H enhances DNA 
replication through bridging interactions between Treslin and TopBP159. The functional 
ramifications of these interactions remain unknown, but we recently showed that the 
oncogenic interaction between mtp53 R273H and PARP1 can be targeted by 
combination treatment of alkylating agent temozolomide and PARP inhibitor talazoparib 
to induce synthetic lethality in mtp53 R273H-containing breast cancer cells58. Inhibition 
of PARP1 has gained traction in the clinic within cancer cells that are deficient in 
homologous recombination, typically through BRCA1 inactivation although cancers 
deficient in other DNA repair pathways are also undergoing clinical trials82,97,98. Here, 
we present evidence that mutant p53 should also be considered as a biomarker for 
evaluating the use of PARP inhibitors or other combination treatment. 
Poly(ADP-Ribose) Polymerase 1, or PARP1, is a protein which catalyzes the 
addition of poly(ADP-ribose) (PAR) chains to targets for the purpose of providing a 
scaffolding for the recruitment of additional proteins typically involved in DNA repair82,106. 
It has also been shown that PARP1 functions as a sensor for unligated Okazaki fragments 
in lagging strand DNA replication by the same means81. The first step in the PARylation 
cascade is that PARP1 self-PARylates. Proteins containing a PAR-binding motif will non-
covalently interact with auto-PARylated PARP1, which will in turn covalently PARylate 
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regions of these proteins82. Wild-type p53 is known to interact with PARP1 in this way 
and makes use of its basic amino acid-rich C-terminal domain (CTD) to non-covalently 
bind auto-PARylated PARP1 before being covalently PARylated at 3 other known sites – 
two in the site-specific DNA binding domain, and one in the oligomerization domain – for 
a total of four known PAR binding motifs107.  
The p53 CTD is a stretch of 30 amino acids from position 364-393 and is comprised 
of six lysine residues (amino acid positions 370, 372, 373, 381, 382, 386) which bind DNA 
independent of sequence through electrostatic interactions with the DNA phosphate 
backbone in addition to undergoing several post-translational modifications, including 
PARylation10,14,15,107-109. We have previously shown that mutant p53 R273H also interacts 
with PARP1, and we hypothesize that this interaction is mediated through the intact CTD 
of mtp53 R273H. More broadly, we predict that the mtp53 R273H-mediated increase of 
PARP1 to chromatin assists in DNA replication and utilizes the R273H CTD for this 
interaction. We predict that the R273H CTD increases the speed of DNA replication by 
recruitment of PARP1 to replicating DNA. The recruitment of more PARP to chromatin 
may result in more efficient DNA replication processivity, particularly at the resolution of 
unligated Okazaki fragments in lagging strand synthesis. Potentially, the recruitment of 
PARP1 may also enhance the capacity for cells to resolve DNA replication stress by 
priming PARP1 to be at replication sites before DNA replication stress occurs.  
Many outstanding questions remain regarding mutant p53 R273H, including the 
mechanism of mutant p53 binding to chromatin and replicating DNA in the absence of 
site-specific DNA binding, as well as the contribution of mutant p53 domains which drive 
gain-of-function phenotypes. Here, we show that the C-terminal domain facilitates the 
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binding of mutant p53 R273H to PARP1 and that the C-terminal domain plays a nuanced 
role in R273H gain-of-function DNA replication and cell cycle progression. These 
observations open the door for potential targeted therapies against cancer cells 
containing GOF mtp53 R273H that are co-opting the DNA replication pathway. 
The contribution of wild-type p53 on DNA replication and replication-coupled 
repair have been closely studied for several years, and while much progress has been 
made in the context of gain-of-function mtp53 in DNA replication55-60, many questions 
remain. Our previous observations of a mtp53-PARP-MCM axis in MDA-MB-468 breast 
cancer cells indicate a direct role for mutant p53 R273H in the regulation of DNA 
replication. Here, we set out to investigate whether DNA replication initiation or 
processivity were influenced by the gain-of-function mutant p53 R273H and whether the 
mutant p53 CTD plays a role in these functions. As mentioned in chapter 1, DNA 
replication initiation is a multi-step process that results in the firing of a licensed 
replication origin. DNA processivity describes the ability of DNA replication to progress 
and resolve stalling from damage and other stress110. There is an observed relationship 
between DNA replication initiation and processivity111,112. Generally, the slower DNA 
replication forks progress, the more origins are fired to make up the timing, and the 
inverse is also true where faster forks result in less origin firing. There is also thought in 
the field that increased origin firing induces replication stress, leading to increased DNA 
damage response, which is thought to provide selective pressure in cancer cells for 
further mutations in the DNA damage response pathway86. In this way, aberrant 
replication origin firing can lead to the progression of cancer and contribute to further 
genomic instability. Interestingly, when cells are treated with hydroxyurea, an agent 
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which reversibly inhibits ribonucleotide reductase, there is decrease in both replication 
fork speed and origin firing113. This indicates that the replication fork speed timing 
mechanisms respond differently to different stressors rather than having a uniform 
response114-116. 
Our group has observed mtp53 protein bound to replicating DNA in association 
with DNA replication licensing factor proteins MCM2-7, PCNA, and PARP1. We have 
also seen that overexpression of mtp53 R273H in MDA-MB-468 cells increases cellular 
proliferation rates56,58. This growing body of evidence suggests a positive transcription-
independent regulatory role for mtp53 in DNA replication initiation and processivity, 
requiring direct mtp53 interaction, which we explored using the DNA fiber assay to track 
replication origin firing rates and replication fork speed117. Previous studies have 
investigated mutant p53 gain-of-function through DNA-binding domain mutations. We 
expand on these studies by investigating the role of the mutant p53 (mtp53) R273H C-
terminal basic domain (CTD). The CTD has several basic charged amino acids 
including six lysine residues known to be important for wild-type p53 to bind DNA non-
specifically. Utilizing triple-negative breast cancer cell line MDA-MB-468, with its mtp53 
R273H C-terminally altered via sgRNA-CRISPR/Cas9 technology (generated by Dr. Jill 
Bargonetti)55, and transient transfection of HCT116 p53-/- cells with mtp53 R273H/CTD 
dual mutant proteins (gifts from Dr. James Manfredi and Dr. Carol Prives), we evaluated 
the contribution of the CTD in chromatin binding, DNA replication, G2/M cell cycle 
progression, and interaction with PARP1 and poly(ADP-ribose) (PAR). The 
CRISPR/Cas9-modified cells have various truncations including introduction of an early 
stop codon ending the protein at amino acid 346 resulting in complete elimination of the 
42 
 
CTD and partial deletion of the oligomerization domain (R273H∆347-393), a small in-
frame deletion at amino acid 381 which removes three of six C-terminal lysine residues 
(R273H∆381-388), and a frameshift at the codon corresponding to amino acid 387 
(R273Hfs387). Interestingly, the proliferation rate of R273H∆347-393 is the lowest of the 
mtp53 dual mutants55. This reduction of proliferation may indicate an accumulation of 
DNA damage through unsensed DNA replication stress, the possibility of which will be 
explored in the next section. 
 
4.2 Results 
 4.2.1 The mutant p53 R273H CTD assists in DNA replication 
Mutant p53 R273H C-terminal alterations result in generally lower protein 
expression compared to the full-length mtp53 R273H, as shown in Figure 4.1A, with 
R273H∆381-388 expressing ~60% (lane 2) and R273H∆347-393 expressing ~40% 
(lane 3) mtp53 relative to the parental MDA-MB-468 cell line. We also observe that the 
R273H∆347-393 protein, which is missing a portion of the oligomerization domain, is 
primarily monomeric in conformation55. In the R273Hfs387 cells, there is very little to no 
mtp53 protein expression and low mRNA, possibly due to nonsense-mediated transcript 
decay (Fig. 4.1A, lane 4, transcription data not shown55). Several other clones were 
generated and characterized as part of our recent work, but only the lines listed above 
were evaluated in this thesis55. 
We have previously reported that mutant p53 R273H is found on replicating DNA 
with PARP1. We hypothesize that the non-specific DNA binding activity of the CTD is 
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important for the R273H mtp53 interaction with replicating DNA. To this end, we 
performed a DNA fiber assay to assess the speed of DNA replication and rate of origin 
firing in MDA-MB-468 cells with R273H mtp53 as compared to mtp53 dual mutants (Fig. 
4.1B). Treatment of all MDA-MB-468 cell lines with hydroxyurea (HU) results in uniform 
reduction of DNA replication speed independent of mtp53 status (Figure 4C, compare 
lighter color to darker color in each pair). Between cell lines treated with HU, there are 
very limited changed in the DNA replication speed, indicating that the R273H CTD does 
not assist in the recovery from HU-induced replication stress. Analysis of DNA fibers 
revealed that in unperturbed cells, there is a sharp decrease in the DNA replication 
speed in cells containing R273H∆381-388 (Fig. 4.1C, compare column 1-dark purple 
and 3-dark red), but a slight increase in DNA replication speed in cells containing 
R273H∆347-393 (Fig. 4.1C, compare 1-dark purple and 5-dark green), and no change 
in DNA replication speed with reduction of mtp53 in R273Hfs387 cells (Fig. 4.1C, 
compare 1-dark purple and 7-dark blue). HU treatment did not significantly influence 
origin firing rates, nor did changes to the mtp53 CTD (Fig. 4.1D). These results indicate 
a role for the mtp53 CTD in DNA replication, where loss of the amino acids 381-388 
revealed a delay in the progression of DNA replication forks, but loss of the entire CTD 
(347-393) increased DNA replication speed and reduction in the protein (R273Hfs387) 
did not influence a change when compared to R273H mtp53 in replication fork 
progression.  
It should be noted that all these experiments were carried out on asynchronous 
populations of cells. As such, it is difficult to assess if changes in the cell cycle 
distribution mask any changes that might be occurring. One strength of this assay is the 
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high sample size (n > 2000 fibers each condition) and although the population evaluated 
was asynchronous, the DNA fiber assay allows us to detect only cells which are actively 
undergoing DNA replication. Nonetheless, there may be clear differences in observing a 
synchronized cell population because evaluation of more distinct stages of S-phase 
(early, middle, late) would be possible compared to only evaluating asynchronous 
populations where all stages of S-phase are present at once and indistinguishable 
within the DNA fiber assay. 
Figure 4.1 – MDA-MB-468 cells harboring CRISPR/Cas9-mediated mutations in the 
C-terminal and Oligomerization domains exhibit altered DNA replication speed 
but not origin firing.  
A) Cells were lysed in RIPA buffer to produce a whole cell extract, and mutant p53 
protein levels were assessed by western blot; Actin is used as a loading control and 
normalizer. B) DNA fiber labeling schematic indicating timing of treatment and iodo-
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deoxy-uridine (IdU) and 5-chloro-2’deoxy-uridine (CldU) incorporation. C) Fork speed 
was determined through measuring the CldU length of double labeled fibers. Based on 
three independent biological replicates. Pairwise comparisons were made using a 
paired two-tailed student’s t-test. ****p < 0.0001 D) Newly labeled origins (defined as 
fibers which have the first label (IdU) flanked by the second label (CldU label). No 
statistically significance was found during pairwise comparison of origin labeling data 
(p>0.05) Based on three independent biological replicates. 
 
4.2.2 The mutant p53 R273H CTD assists in G2/M cell cycle progression 
Previously, we evaluated the MDA-MB-468 CRISPR mutant p53 cells cell cycle 
progression changes by flow cytometry and observed small delays in the progression of 
cells containing R273H∆381-388 and R273H∆347-393 mutations and a large delay in 
cells containing the R273Hfs387 mutation55. Here, we expanded investigation of cell 
cycle progression and evaluated the progression of mtp53 dual mutants through G2/M 
via flow cytometry following synchronization with Aphidicolin for 24 hours followed by 
release into fresh cell culture media. We observe that cells harboring the R273H∆381-
388 mutant progressed much slower through G2/M phase to complete the cell cycle 
compared to both full length R273H and R273H∆347-393, particularly between hours 
12-16 following release from Aphidicolin (Fig. 4.2A-C). Interestingly, by hour 20 we 
observed that cells containing the R273H∆381-388 mutant recovered to match the other 
examined cells. In the case of R273H∆381-388, this delay in G2/M progression agrees 
with reduced DNA replication speed through S-phase, which may result in the delayed 








Figure 4.2 – Cells harboring mutant p53 R273H∆381-388 have delayed G2/M cell 
cycle progression.  
A) Cells were synchronized with aphidicolin for 24 hours and cell cycle progression was 
tracked by flow cytometry for 0, 12, 16, 18, and 20 hours after aphidicolin release. 
Selected time points are represented from one biological replicate; Based on three 
independent biological replicates. B) Population of cells in G1 phase over time following 
aphidicolin block and release. p<0.05 based on three independent biological replicates. 
C) Population of cells in G2/M over time following aphidicolin block and release. 




Figure 4.3 – Mutant p53 requires an intact C-terminal domain to co-localize with 
PARP1 and poly(ADP-Ribose).  
A) Proximity ligation assay between mutant p53 and PARP1. PLA signal is shown in grayscale. 
As a negative control, MDA-MB-468 cells were stained with only p53 primary antibody, 
resulting in no PLA amplification. Three independent biological replicates were performed. 
Scale bar = 25uM (This experiment was performed by George Annor). Based on three 
independent biological replicates. B) Analysis of the mtp53/PARP1 proximity ligation assay, 
based on automated segmentation and counting with Cell Profiler and statistical evaluation in 
Graphpad Prism 9. C) Proximity ligation assay between p53 and poly(ADP-Ribose) (PAR). 
Scale bar = 25uM. Based on three independent biological replicates. (D) Analysis of the 
mtp53/PAR proximity ligation assay based on identical automated segmentation and counting 
settings by Cell Profiler as in panel B and statistical evaluation in Graphpad Prism 9.  
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4.2.3 PARP1 and poly-ADP-ribose interact with mutant p53 R273H through 
the CTD 
We previously showed that mutant p53 R273H upregulates the chromatin 
localization of PARP1 and both proteins can be found at replication forks in triple-
negative breast cancer cells. PARP1 is an enzyme that catalyzes the production of 
poly(ADP-ribose) (PAR) chains to post-translationally modify proteins and nucleic acids.  
PARP1 functions in the DNA replication stress response by sensing unligated Okazaki 
fragments and facilitating recruitment of factors FEN1 and Lig1 for efficient resolution of 
Okazaki fragments81. It has been shown by others that wild-type p53 interacts with 
PARP1 through the CTD by binding non-covalently to auto-PARylated PARP1, allowing 
subsequent covalent PARylation of p53 at distinct regions in the N-terminus and DNA 
binding domain107. We therefore hypothesize that the mtp53 CTD is critical for 
interaction between mtp53, PARP1, and PAR. Therefore, we performed proximity 
ligation and co-immunoprecipitation assays to assess the ability for mtp53 dual mutants 
to bind and localize to PAR and PARP1. By proximity ligation assay, we observed a 
reduction in co-localization between PARP1 and p53 with the R273H∆381-388 mutant, 
and a further reduction with the R273H∆347-393 mutant (Fig. 4.3 A-B). Furthermore, we 
observed a similar reduction in the co-localization between mtp53 and PAR with both 
R273H∆381-388 and R273H∆347-393 (Fig. 4.3 C-D). The reduction in mtp53-PARP1 
interaction is mirrored in the co-immunoprecipitation where mtp53 is pulled down and 
PARP1 is probed for, comparing lanes 3, 6, and 9 (Fig. 4.4). It should be noted that 
while the proximity ligation assay can be used to determine co-localization within 30nm, 
and the co-immunoprecipitation determines protein-protein interaction,  
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there is still the possibility of an intermediate bridging protein facilitating indirect binding 
of mtp53 R273H to PAR or PARP1. Also, specifically in the case of the proximity ligation 
assay, one may argue that changes in co-localization are reflective of the relative 
differences in mtp53 R273H protein levels expressed in the CTD dual-mutant lines, 
rather than due to decreased mtp53-PARP1 binding affinity. However, the co-
immunoprecipitation assay resolves this issue because the p53-specific pulldown in 
each cell line is roughly equal between clones and the co-immunoprecipitation of 
PARP1 decreases with both R273H∆381-388 and R273H∆347-393 clones, indicating 
that the CTD is indeed a critical domain for direct or indirect interactions with PARP1. 
Due to the nature of PARP1 auto-PARylation facilitating interactions with wtp53107, it 
stands to reason that the interaction between mtp53 R273H and PARP1 is mediated by 
PAR as a post-translational modification of both mtp53 and PARP1. 
Figure 4.4 – Mutant p53 requires a C-terminal domain to pull-down PARP1 
A) Co-immunoprecipitation examining the interaction of PARP1 and the mtp53 C-
terminal domain. Input is 1% of the whole cell lysate used for the pull-down. 




Our data reveal that the portions of the mutant p53 R273H CTD influence the 
speed of DNA replication and progression through G2/M of the cell cycle. Paradoxically, 
while deletion of mutant p53 R273H amino acids 381-388 resulted in slowed DNA 
replication and delayed G2/M progression, deletion of amino acids 347-393 increased 
replication speed, and reduced expression of R273H (as seen in R273Hfs387) show no 
change in DNA replication speed. The DNA replication speed results appear to be 
relatively independent of the level of mtp53 protein expressed in each cell line, 
especially in the case of R273H∆347-393 clone which had increased DNA replication 
speed with reduced protein expression, and in the case of the R273Hfs387 clone with 
very little mtp53 protein expression, DNA replication speed was only slightly reduced 
compared to the parental MDA-MB-468 cell line. 
One possible explanation for unaltered replication fork speed in the case of the 
R273H∆347-393 clone is that the deletion from amino acids 347-393 includes a portion 
of the oligomerization domain, and tetramerization of mutant p53 R273H may be 
required for binding to DNA. An absence of DNA binding from R273H∆347-393 could 
eliminate any proposed replication function, though in our hands there is still a small 
amount of chromatin binding possible by the R273H∆347-393 protein55. We observed 
via glutaraldehyde crosslinking that the oligomerization state of the R273H∆347-393 is 
disrupted and the predominant state of the protein is a monomer55, but that  
tetramerization of mutant p53 R273H is not required to bind to chromatin (data from 
George Annor, not shown, manuscript in prep). However, chromatin binding does not 
necessarily indicate binding to replication forks specifically, and work is ongoing to 
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address the relative ability of R273H∆347-393 to bind to replicating DNA via the 
isolation of proteins on nascent DNA (iPOND) and EdU-PLA assays. An additional layer 
of complexity exists for this experimental set-up, because the relative level of R273H 
protein expression is reduced in R273H∆381-388 (~60%) and R273H∆347-393 
(~40%)55. Reduced protein expression in these lines will likely lead to observing less 
interaction with replicating DNA as a function of there being less overall mutant p53 
protein expressed in these cells. Therefore, one important interpretation of these results 
is that there is a dose-dependent effect of mutant p53 R273H, in addition to any 
potential contribution of the CTD or oligomerization state. 
Another compelling possibility is that R273H∆347-393, which exhibits the lowest 
proliferation and lowest interaction with PAR and PARP1, has a reduced ability to sense 
and resolve DNA replication stress. This theory is supported by observations that PARP 
inhibition leads to increased DNA replication fork speeds resulting in a loss of sensing 
unligated Okazaki fragments, and an accumulation of DNA damage throughout the cell 
cycle as a result86,87. This potential explanation has been incorporated into a model for 
our interpretation of how the CTD is participating in R273H gain-of-function by 
increasing the amount of chromatin-bound PARP1 and supporting efficient resolution of 
unligated Okazaki fragments. 
A significant limitation of this work is the use of only asynchronous cell 
populations and generally populations unperturbed by DNA damage for the evaluation 
of DNA replication speed. The role of R273H mutant p53 may be to help resolve DNA 
replication stress by facilitating PARP1 activity, and in the absence of stress, the 
behavior is not needed. Our group explored similar ideas when we recently observed 
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that following release from excess thymidine, the R273H∆381-388, R273H∆347-393, 
and R273Hfs387 cells experience delays in S-phase progression55. There were no 
differences in S-phase progression following release from either aphidicolin or 
hydroxyurea, indicating that mutant p53 functions different in response to various forms 
of replication stress. Nevertheless, removal of amino acids 381-388 decrease DNA 
replication speed even in the absence of any DNA damage, which hints at a larger role 
for the CTD in regulating DNA replication.  
In the future, we will examine the role of the mtp53 R273H CTD in DNA 
replication more specifically. It is possible that the cells are experiencing replication 
uncoupling between the leading and lagging strands, resulting in increased replication 
stalling and damage118,119. Fork stalling rates can be assessed with our existing DNA 
fiber data to measure the degree of asymmetry in double labelled bi-directional forks. 
Increased damage could be sustained in the absence of the R273H mutant protein, 
where there is a decrease in PARP1 chromatin localization and possibly a loss of 
sensing DNA replication stress in the form of unligated Okazaki fragments. This lack of 
sensing unligated Okazaki fragments could lead to leading and lagging strand uncouple 
and an increase in genomic instability. 
When examining the cell cycle progression of the mtp53 R273H CTD dual 
mutants, we observed that deletion of amino acids 381-388 produces a delay in the 
timely completion of G2/M before cells re-enter G1. Presently, it is not clear what the 
mechanism of this delay is, but it is known that both p53 and PARP1 participate in 
mitotic progression by regulating centrosome function, partially through the direct 
PARylation of p53 by PARP1120. The interaction between these proteins could be the 
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key to delays in mitotic progression when amino acids 381-388 are lost. To that end, we 
evaluated the interaction between mtp53 and PARP1, as well as mtp53 and PAR, and 
observed that loss of amino acids 381-388 in mtp53 R273H reduced the interaction 
between mtp53, PARP1, and PAR. We also observed that R273H∆347-393 had an 
even lower interaction with PARP1 and PAR, indicating that the CTD is critical for these 
interactions. However, cells expressing R273H∆347-393 showed no delay in the 
progression of G2/M, mirroring the progression of cells with full-length mtp53 R273H.  
Another possibility for delayed G2/M progression for R273H∆381-388 could be 
related to the delay in DNA replication seen by the DNA fiber data. It is possible that 
slower DNA replication speed leaves the genome not fully duplicated by the end of S-
phase, and G2/M delay is brought on until replication is complete. However, in addition 
to the data shown with aphidicolin synchronization and release at the start of S-phase, 
we also performed synchronization at the border of mitosis using nocodazole for 12 
hours (data not shown), which would provide time to resolve unreplicated DNA leftover 
from S-phase, and we still observed a G2/M progression delay. This indicates the G2/M 
delay may be a direct result of problems in mitosis rather than cells struggling to exit S-
phase. One way to assess this is to perform mitotic scoring of cells121 and evaluate 
whether there is a mitotic structure over-represented in the R273H∆381-388 cells. For 
example, if there is an overabundance of metaphase cells, this may indicate a defect in 
the mitotic spindle checkpoint or with chromosomal segregation and give an idea as to 






















The study of mutant p53 has been the subject of much interest over the decades 
due to the stable expression of missense mt53 that has lost tumor suppressor activity in 
human cancer. Considering the increasing number of roles of mutant p53 and the 
complexity of the dynamics within cancer cells, this is likely to remain the case for the 
foreseeable future. In this thesis, data was presented that mutant p53 V274F and 
P223L are not drivers of gain-of-function PARP inhibitor sensitivity in DU145 cells. 
Interestingly, in the context of the temperature sensitive P223L, which reverts the 
protein to a wild-type conformation at 32oC, DU145 exhibited decreased sensitivity to 
combination DNA damage and PARP inhibition treatment, indicating wild-type p53 is an 
inhibitor of sensitivity. 
In this body of work, we also show that one of the most common mutant p53 
proteins, R273H, can assist DNA replication and cell cycle progression through use of 
key residues in the C-terminal basic domain, as seen when these residues are lost 
(R273H∆381-388). A dynamic at play which is poorly understood is the observation that 
loss of the entire C-terminal basic domain and a portion of the oligomerization domain 
(R273H∆347-393) or a sharp decrease in mutant p53 expression (R273Hfs387) did not 
result in slowed DNA replication and progression through G2/M in the cell cycle. More 
experiments with synchronized cells may help to dissect out the variable functions of 
mtp53 domains in replication and cell cycle control. For example, evaluation of 
processivity and origin firing through early-, middle-, and late-S-phase would be 
possible using synchronized cultures and would provide insight as to the timing of 
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mutant p53 assisting in DNA replication. Understanding the mechanism of mutant p53 
R273H assisting DNA replication may also reveal the underlying issue that R273H∆381-
388 cells experience when undergoing delayed progression through G2/M. More work 
will need to be done to clearly dissect the role of the mtp53 R273H CTD in DNA 
replication and cell cycle progression. 
5.2 Preliminary data and future directions 
 As mentioned in Chapter 4, we previously described mutant p53 R273H as 
binding directly to replicating DNA56. As part of that published work, we also show that 
in addition to R273H, mutant p53 R248W also binds to replicating DNA. The cell system 
used for these experiments involve MDA-MB-468 cells, which have endogenous 
expression of R273H, and an exogenous overexpression system in which the cells 
express FLAG-tagged mutant p53 R248W. This system is showcased in figure 5.1A 
where both p53 and FLAG are probed for in a chromatin fractionation, indicating that 
both R273H and FLAG-R248W are present and localize to chromatin. In the following 
panel, we performed a PLA between either mtp53/EdU or FLAG/EdU (Fig. 5.1B). As 
such, the system cannot distinguish between R273H and R248W, but the colocalization 
of FLAG and EdU indicates that R248W is localized to replicating DNA. We have shown 
clearly that R273H performs this function on its own, but this experiment leaves the 
possibility that R248W is forming mixed oligomers with R273H, which is then localizing 
to replicating DNA. As a proof of principle, I performed an isolation of proteins on 
nascent DNA (iPOND) to reproduce data from Xiao 202056 (Figure 5.1 C and D). We 
observe that we retain some replicating DNA following the sonication steps in the 
iPOND lysis (Figure 5.1 C comparing lanes 1 and 2 before sonication to lanes 3 and 4 
57 
 
after sonication) (procedure described in depth in Chapter 2.12). Following the DNA 
fragmentation, we performed the pulldown of nascent DNA and probed for PCNA as a 
control for pulling down replicating DNA, and also mutant p53 R273H, which we see 
associated with replicating DNA compared to the input (Figure 5.2 D compare lane 1 
and 2). Follow-up experiments would include performing the iPOND on R273H∆381-388 
and R273H∆347-393 cells to determine if these CTD-truncated variants of R273H also 
associate with replicating DNA. This data would help clarify the participation of the 
mutant p53 R273H CTD in DNA replication, as interaction with replicating DNA has not 
yet been confirmed for the CTD dual mutants. A follow-up experiment to confirm R248W 
recruitment to replicating DNA could be to transfect R248W plasmid into p53-null cells 
and examine the EdU-PLA in that context, or also attempt the iPOND, though the 
transfection efficiency may be too low to generate enough starting material for an 
iPOND pulldown. These experiments would be worthwhile because while there is 
significant overlap with mutant p53 proteins, they also at times exhibit unique properties 
from one another, and these data could provide clinical benefit when evaluating patients 
with mutant p53 by having mechanistic insights into each hotspot mutant’s contribution 





Figure 5.1 – Mutant p53 R273H and R248W bind to chromatin and replicating DNA 
A) Representative western blot showing expression of mtp53 R273H and FLAG-R248W in the 
background of MDA-MB-468 cells. B) Proximity ligation assay between mtp53/EdU or FLAG/EdU. 
Based on three independent biological replicates. Figure 5.1A and 5.1B were published as part of 
Xiao et. al49. C) DNA fractionation following iPOND lysate procedure on MDA-MB-468 cells prior to 
pull-down of nascent DNA. D) iPOND analysis pulling down nascent DNA and association of mutant 
p53 R273H and PCNA with nascent DNA in MDA-MB-468 cells. PCNA was used as a positive 
control for pulldown of replicating DNA. Based on two biological replicates in my hands, but 




Along this line of thought, we evaluated the chromatin binding of several hotspot 
mutations in the context of transfected p53-null H1299 cells. First, we evaluated the 
Neon electroporation system and titrated the amount of p53 plasmid introduced into 
H1299 p53-null cells and compared the protein expression to MDA-MB-468 which 
endogenously express R273H (Fig. 5.2A). We determined using these conditions that 
1ug of plasmid DNA was comparable to the R273H expression in MDA-MB-468 (Fig 
5.2A comparing lane 5 and 6) and continued to use 1ug for the duration of the 
electroporation experiments. Next, we introduced 1ug each of the most common 
hotspot mutations, R175H, R248Q, and R273H as well as dual mutants where each 
hotspot mutant had the final 24 amino acids deleted (each a generous gift from Dr. Jim 
Manfredi) and performed a whole cell lysis (Fig. 5.2B). We observe that the wild-type 
p53 and wild-type∆24 proteins are expressed at a lower level compared to the mutant 
p53 proteins (Fig. 5.2B lane 2 and 3 compared to lanes 4-9). This could possibly be due 
to wild-type p53 activating its negative feedback loop leading to its degradation and is in 
general agreement with the idea that mutant p53 is more stable than wild-type p53. We 
also observe the mobility shift between each full-length protein and its CTD-truncated 
partner, indicating that the ∆24 proteins are indeed truncated (comparing even 
numbered lanes to odd numbered lanes). Next, we transfected H1299 cells with 1ug of 
plasmid and performed a chromatin fractionation for wild-type p53 and R273H, as well 
as their ∆24 counterparts (Fig. 5.2C). We expected the chromatin binding of these 
hotspot mutants to be intact and predicted that the CTD was being used to allow these 
mutants to bind to chromatin. Therefore, we also utilized CTD-truncated versions of the 
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same mutants and assessed whether chromatin binding decreased. We observed that 
each hotspot mutant localized to chromatin (Fig 5.2C lanes 7 and 9) and that truncation 
of the CTD reduced that binding, although modestly compared to what we expected 
considering the CTD is the only known non-specific DNA binding domain in the protein 
and has been removed (Fig. 5.2C lanes 8 and 10 compared to lanes 7 and 9). We see a 
roughly four-fold reduction in wild-type p53 binding to chromatin and roughly two-fold 
reduction in R273H binding to chromatin when the CTD is truncated. However, in both 
cases, there is still clearly chromatin engagement for wild-type and mutant p53 lacking 
the final 24 amino acids that make up the CTD. This indicates that indeed the CTD 
plays a role in the chromatin binding of these mutant p53 proteins but is not the only 
factor driving the chromatin interactions of mutant p53. One potential explanation is that 
the chromatin localization of mtp53 relies on protein-protein interactions rather than 





Figure 5.2 – The hotspot mutant p53 proteins R175H, R248Q, and 
R273H utilize the CTD to bind chromatin. 
A) Transfection titration in p53-null H1299 cells. Varying concentrations of 
pCMV-FLAG-R273H plasmid was transfected into cells using NeoN 
electroporation (1700V/25ms/1 pulse) and cells are probed with either p53 or 
FLAG antibody. MDA-MB-468 is used as a control cell line expressing 
endogenous R273H. B) Whole cell lysate and western blot of transfection of 
H1299 cells with common hotspot mutant p53 and CTD-truncated p53 (∆24) 
(plasmids were in a pCMV-FLAG-p53 backbone, each gifted by Dr. Jim 
Manfredi). Actin is used as a loading control C) Chromatin fractionation of 
H1299 transfected cells. Actin is used as a cytosolic loading control and lamin is 




We also obtained plasmids from the Carol Prives lab where the six lysine resides 
in the wild-type p53 CTD were mutated to either arginine (6KR) or glutamine (6KQ). 
Altering lysine to arginine maintains the positive charge of lysine but blocks post-
translational modifications, while mutating to glutamine neutralizes charge and mimics 
constitutive acetylation of the CTD38. Previously, the CTD lysine residues have been 
studied in wild-type p53 to evaluate the contribution of the CTD in transcriptional 
activation of p53 targets, as well as for protein stability, interaction with PARP and PAR, 
and in vivo development of mice33,36-38,107. We utilized site-directed mutagenesis on 
these plasmids to create several p53 dual mutant plasmids where a hotspot mutation is 
introduced to either the 6KR or 6KQ plasmids. We were able to introduce hotspot 
mutations R175H, R248Q, and R273H into both 6KR and 6KQ backgrounds. 
Preliminary work with these plasmids so far has included transfection into p53-null 
HCT116p53-/- cells. We have used these transfections to evaluate the chromatin 
binding of these R273H dual mutant p53 proteins (Fig. 5.3 A) Since the CTD utilizes 
electrostatic interactions to bind to DNA non-specifically, we predicted that the 6KR 
mutants would retain chromatin binding because they retain their charge. We also 
predicted that the 6KQ proteins would have less chromatin binding since they have lost 
their charge, and mimic acetylation which is known to reduce p53 chromatin 
interactions. We found that there are minimal changes to chromatin binding, and both 
the 6KR and 6KQ proteins are still bound to chromatin to a high degree compared to 
R273H (Fig. 5.3 A comparing lane 5, 6, and 7). We see a reduction in R273H∆24 
binding to chromatin (Fig. 5.3 A comparing lanes 5 and 8), in agreement with Fig. 5.2 C. 
We also performed a co-immunoprecipitation with lysates from transfected cells, pulling 
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down p53 and probing for PARP1 (Fig. 5.3 B). Interestingly, the R273H6KQ protein has 
strong interaction with PARP1 (Fig. 5.3 B lane 9) while the R273H6KR proteins interact 
very weakly with PARP1 (Fig. 5.3 B lane 6), even less than the R273H∆24 protein (Fig. 
5.3 B lane 12). This observation is surprising because glutamine is not PARylated, and 
does not bind to PAR, both of which are the usual way proteins interact with PARP1. 
Also quite interesting is that loss of the entire CTD in the R273H∆24 cells retain some 
interaction with PARP, but alteration of CTD lysine to arginine drastically reduces the 
interaction. The CTD facilitates the interplay between p53 and PARP1 and is a major 
region for PAR binding, but there are also three additional PAR binding motifs in the 
DNA binding and oligomerization domains of the protein107. While the other three PAR 
binding motifs have been shown to have only minor contribution to PAR and PARP 
interaction compared to the CTD PAR binding motif in wild-type p53107, it is possible 
that they are alternative sites for PARP interaction in our mutant p53 R273H CTD dual 
mutant proteins. 
These observations warrant follow-up and could be explored further by treating 
transfected cells with a de-PARylation inhibitor, PARGi, or inducing DNA damage with 
an agent like temozolomide, to see if increasing the stability of PAR or activation of 
PARP1 increases the interaction between any of the transfected constructs and PARP1. 
This would give an indication of whether PARylation is mediating the interaction 
between mtp53 CTD and PARP1, or if the interaction is happening through another 
mechanism such as direct binding to unmodified PARP1 or interaction through an 





Figure 5.3 Mutant p53 R273H6KQ binds tightly to chromatin and PARP1 
A) Chromatin fractionation using HCT116p53-/- cells transfected with indicated plasmids 
via lipofectamine protocol. Lamin is used as a chromatin loading control and Actin is 
used as a cytosolic loading control. Based on two independent biological replicates. B) 
Co-immunoprecipitation using HCT116p53-/- cells transfected with indicated plasmids via 
lipofectamine protocol. Based on one independent biological replicate. 
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 The complexity of mutant p53 continues to grow by the day, especially in light of 
increasing studies on gain-of-function mutant p53. For this work we evaluated the 
contribution of the CTD in mtp53 R273H gain-of-function DNA replication and cell cycle 
progression. We were to determine that truncation at amino acids 381-388 reduced the 
speed of DNA replication and progression through G2/M in the unperturbed cells, while 
deletion of amino acids 347-393 or frameshift-mediated depletion of mtp53 R273H had 
no impact on DNA replication speed. We also show that mtp53 R273H interaction with 
PARP1 and PAR is greatly reduced in the case of both R273H∆381-388 and 
R273H∆347-393. These findings are summarized in figure 5.4. We speculate that the 
CTD assists mtp53 R273H recruit PARP1 to chromatin for the efficient resolution of 
unligated Okazaki fragments that occur in DNA replication. Here, we propose a 
speculative model to be interrogated further, where recruitment of PARP1 to sites of 
DNA damage by mtp53 R273H depends on its CTD. In the presence of DNA damage 
and partial loss of the CTD, DNA replication is slowed due a reduced ability to recognize 
and resolve this stress. In the case of total loss of the CTD and part of the OD, the 
mtp53-PARP/PAR complex is reduced, and we speculate that unligated Okazaki 
fragments are not sensed, leaving DNA replication speed high, but overall proliferation 
and genomic stability impaired due to the persistence of unresolved Okazaki fragment 
gaps. The rationale for this speculation is based on observations that inhibition of 
PARP1 leads to an increase in DNA replication fork speed without altering replication 
initiation rates, and a decrease in cellular proliferation87 – all in agreement with our 
observations in the case of the cell line expressing R273H∆347-393. Clearly, there is 
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much more to be uncovered about mutant p53, and the promise is still great for the 







Figure 5.4 Summary data table and proposed model 
A summary data table and schematic summarizing the findings of the contribution of the 
mtp53 R273H CTD in DNA replication, PARP/PAR binding, and proposed resolution of 
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